Passer au contenu principal

Subventions financées

Filtrer par:
Effacer les filtres
Filtrer par:

831 résultats trouvés

Using a virtual care platform to deliver peer-led mental health support to rural and remote communities in BC: A randomized wait-list controlled trial of the REACHOUT intervention

Dr. Tang and her team at the University of British Columbia will use a virtual care platform to deliver peer-led mental health support to rural and remote communities in BC, through an intervention called REACHOUT, created with support from a previous JDRF grant.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Colombie-Britannique
DATE DE DÉBUT
2022

Teaching Adolescents with type 1 Diabetes Self-compassion (TADS) to reduce diabetes distress: A randomized controlled trial

Self-compassion is a practice that involves acting the same way towards yourself as you would with friends and loved ones, and that you are kind and understanding towards yourself.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Ontario
DATE DE DÉBUT
2022

TECC-T1D3: Technology-enabled Comprehensive Care for young adults with Type 1 Diabetes and Diabetes Distress

Diabetes distress, the negative emotional feelings resulting from living with diabetes and the burden of selfmanagement, is a very common challenge for people living with type 1 diabetes affecting approximately 40%.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Santé mentale
Concours
FRDJ Canada - Brain Canada Subventions aux équipes de lutte contre le diabète de type 1 pour la santé mentale
Province
Ontario
DATE DE DÉBUT
2022

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

Rationale: Mitochondrial dysfunction has been identified as a contributing factor for bioenergetic dysregulation and neurodegeneration in the motor cortex and spinal cord of patients with ALS.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Determination of hypothalamic neuropathology and metabolic defects in ALS

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease leading to paralysis and death within 2-5 years from disease onset.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Novel biomarkers of SOD1 pathology in familial and sporadic ALS

Mutations in the SOD1 gene, leading to the misfolding and toxic aggregation of SOD1 protein, are the second leading cause of Familial Amyotrophic Lateral Sclerosis (FALS-SOD1) and emerging literature has detected misfolded SOD1 (mSOD1) in the cerebrospinal fluid (CSF) and post-mortem tissue of Sporadic ALS (SALS) patients.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2022

Identification of Protein Interactions That Regulate FUS Mislocalization and Aggregation in ALS

Amyotrophic lateral sclerosis (ALS) is a debilitating and terminal disease.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Imaging a New ALS Biomarker in the Eye

Current biomarkers of ALS used by clinicians to help care for ALS patients have many drawbacks that may include cost, accessibility, and invasiveness of procedures.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Effects of C9orf72 Deficiency on Inducing Neuronal Hyperexcitability In Vivo

A G4C2 repeat expansion in C9orf72 (chromosome 9 open reading frame 72), a gene of unclear function, is the most frequent genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (C9-ALS/FTD).


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Exploring the involvement of TDP-43 SUMOylation in ALS pathogenesis

TDP-43 is an essential DNA/RNA binding protein at the epicenter of Amyotrophic Lateral Sclerosis (ALS).


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022